Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Colorectal Neoplasms

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 136 articles:
HTML format
Text format



Single Articles


    May 2017
  1. JINGU K, Matsuo Y, Onishi H, Yamamoto T, et al
    Dose Escalation Improves Outcome in Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer.
    Anticancer Res. 2017;37:2709-2713.
    PubMed     Text format     Abstract available


  2. JI WB, Um JW, Ryu JS, Hong KD, et al
    Clinical Significance of 5-Fluorouracil Chemosensitivity Testing in Patients with Colorectal Cancer.
    Anticancer Res. 2017;37:2679-2682.
    PubMed     Text format     Abstract available


  3. IRABOR DO, Oluwasola OA, Ogunbiyi OJ, Ogun OG, et al
    Microsatellite Instability Is Common in Colorectal Cancer in Native Nigerians.
    Anticancer Res. 2017;37:2649-2654.
    PubMed     Text format     Abstract available


  4. SASAKI S, Ueda M, Iguchi T, Kaneko M, et al
    DDR2 Expression Is Associated with a High Frequency of Peritoneal Dissemination and Poor Prognosis in Colorectal Cancer.
    Anticancer Res. 2017;37:2587-2591.
    PubMed     Text format     Abstract available


  5. DRESSEN K, Hermann N, Manekeller S, Walgenbach-Bruenagel G, et al
    Diagnostic Performance of a Novel Multiplex Immunoassay in Colorectal Cancer.
    Anticancer Res. 2017;37:2477-2486.
    PubMed     Text format     Abstract available


  6. GOMBODORJ N, Yokobori T, Yoshiyama S, Kawabata-Iwakawa R, et al
    Inhibition of Ubiquitin-conjugating Enzyme E2 May Activate the Degradation of Hypoxia-inducible Factors and, thus, Overcome Cellular Resistance to Radiation in Colorectal Cancer.
    Anticancer Res. 2017;37:2425-2436.
    PubMed     Text format     Abstract available


  7. SATO K, Masuda T, Hu Q, Tobo T, et al
    Phosphoserine Phosphatase Is a Novel Prognostic Biomarker on Chromosome 7 in Colorectal Cancer.
    Anticancer Res. 2017;37:2365-2371.
    PubMed     Text format     Abstract available


  8. YUEH TC, Chou AK, Gong CL, Fu CK, et al
    The Contribution of Excision Repair Cross-complementing Group 1 Genotypes to Colorectal Cancer Susceptibility in Taiwan.
    Anticancer Res. 2017;37:2307-2313.
    PubMed     Text format     Abstract available


  9. UEDA M, Iguchi T, Masuda T, Komatsu H, et al
    Up-regulation of SLC9A9 Promotes Cancer Progression and Is Involved in Poor Prognosis in Colorectal Cancer.
    Anticancer Res. 2017;37:2255-2263.
    PubMed     Text format     Abstract available


    April 2017
  10. STOTZ M, Herzog SA, Pichler M, Smolle M, et al
    Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients.
    Anticancer Res. 2017;37:2011-2018.
    PubMed     Text format     Abstract available


  11. BASSO SM, Lumachi F, Pianon P, Fanti G, et al
    Analysis of Factors Affecting Short-term Results in Elderly Patients Undergoing Elective Surgical Resection for Stage I-II Colon Cancer.
    Anticancer Res. 2017;37:1971-1974.
    PubMed     Text format     Abstract available


  12. BUNDSCHERER AC, Malsy M, Bitzinger DI, Wiese CH, et al
    Effects of Lidocaine on HT-29 and SW480 Colon Cancer Cells In Vitro.
    Anticancer Res. 2017;37:1941-1945.
    PubMed     Text format     Abstract available


  13. SKERENOVA M, Halasova E, Matakova T, Jesenska L, et al
    Low Variability and Stable Frequency of Common Haplotypes of the TP53 Gene Region in Colorectal Cancer Patients in a Slovak Population.
    Anticancer Res. 2017;37:1901-1907.
    PubMed     Text format     Abstract available


  14. FORSBERG A, Keranen A, VON Holst S, Picelli S, et al
    Defining New Colorectal Cancer Syndromes in a Population-based Cohort of the Disease.
    Anticancer Res. 2017;37:1831-1835.
    PubMed     Text format     Abstract available


  15. JANG HH, Lee HN, Kim SY, Hong S, et al
    Expression of RNA-binding Motif Protein 3 (RBM3) and Cold-inducible RNA-binding protein (CIRP) Is Associated with Improved Clinical Outcome in Patients with Colon Cancer.
    Anticancer Res. 2017;37:1779-1785.
    PubMed     Text format     Abstract available


  16. PINTOVA S, Planutis K, Planutiene M, Holcombe RF, et al
    ME-143 Is Superior to Genistein in Suppression of WNT Signaling in Colon Cancer Cells.
    Anticancer Res. 2017;37:1647-1653.
    PubMed     Text format     Abstract available


  17. KOTAKE Y, Arikawa N, Tahara K, Maru H, et al
    Y-box Binding Protein 1 Is Involved in Regulating the G2/M Phase of the Cell Cycle.
    Anticancer Res. 2017;37:1603-1608.
    PubMed     Text format     Abstract available


  18. KINDLER C, Smedh K, Chabok A, Shetye J, et al
    Detection of Free Cancer Cells in Pelvic Lavage with Double Immunocytochemistry at Rectal Cancer Surgery.
    Anticancer Res. 2017;37:1563-1568.
    PubMed     Text format     Abstract available


  19. VOGL UM, Ohler L, Rasic M, Frischer JM, et al
    Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy.
    Anticancer Res. 2017;37:1947-1955.
    PubMed     Text format     Abstract available


    March 2017
  20. FUJIKAWA H, Toiyama Y, Inoue Y, Imaoka H, et al
    Prognostic Impact of Preoperative Albumin-to-Globulin Ratio in Patients with Colon Cancer Undergoing Surgery with Curative Intent.
    Anticancer Res. 2017;37:1335-1342.
    PubMed     Text format     Abstract available


  21. YOON YS, Kim CW, Roh SA, Cho DH, et al
    Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer.
    Anticancer Res. 2017;37:1297-1303.
    PubMed     Text format     Abstract available


  22. SEPAROVIC D, Shields AF, Philip PA, Bielawski J, et al
    Altered Levels of Serum Ceramide, Sphingosine and Sphingomyelin Are Associated with Colorectal Cancer: A Retrospective Pilot Study.
    Anticancer Res. 2017;37:1213-1218.
    PubMed     Text format     Abstract available


  23. TRESKA V, Fichtl J, Bruha J, Liska V, et al
    Liver Resections for Colorectal Metastases in Patients Aged Over 75 Years.
    Anticancer Res. 2017;37:1529-1533.
    PubMed     Text format     Abstract available


  24. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Anticancer Res. 2017;37:1501-1505.
    PubMed     Text format     Abstract available


  25. LEE IH, Hwang S, Lee SJ, Kang BW, et al
    Systemic Inflammatory Response After Preoperative Chemoradiotherapy Can Affect Oncologic Outcomes in Locally Advanced Rectal Cancer.
    Anticancer Res. 2017;37:1459-1465.
    PubMed     Text format     Abstract available


  26. ETO K, Kondo I, Kosuge M, Ohkuma M, et al
    Enhanced Recovery After Surgery Programs for Laparoscopic Colorectal Resection May Not Need Thoracic Epidural Analgesia.
    Anticancer Res. 2017;37:1359-1364.
    PubMed     Text format     Abstract available


  27. SIDERIS M, Moorhead J, Diaz-Cano S, Haji A, et al
    KRAS Mutant Status May Be Associated with Distant Recurrence in Early-stage Rectal Cancer.
    Anticancer Res. 2017;37:1349-1357.
    PubMed     Text format     Abstract available


  28. KUBO T, Hirohashi Y, Matsuo K, Sonoda T, et al
    Mismatch Repair Protein Deficiency Is a Risk Factor for Aberrant Expression of HLA Class I Molecules: A Putative "Adaptive Immune Escape" Phenomenon.
    Anticancer Res. 2017;37:1289-1295.
    PubMed     Text format     Abstract available


  29. DANIELE A, Divella R, Abbate I, Casamassima A, et al
    Assessment of Nutritional and Inflammatory Status to Determine the Prevalence of Malnutrition in Patients Undergoing Surgery for Colorectal Carcinoma.
    Anticancer Res. 2017;37:1281-1287.
    PubMed     Text format     Abstract available


  30. LYBEROPOULOU A, Galanopoulos M, Aravantinos G, Theodoropoulos GE, et al
    Identification of Methylation Profiles of Cancer-related Genes in Circulating Tumor Cells Population.
    Anticancer Res. 2017;37:1105-1112.
    PubMed     Text format     Abstract available


  31. RUBIO CA
    The Histogenesis of the Third Pathway of Colonic Carcinogenesis in Rats.
    Anticancer Res. 2017;37:1039-1042.
    PubMed     Text format     Abstract available


  32. DOGAN A, Schultheis B, Rezniczek GA, Hilal Z, et al
    Synchronous Endometrial and Ovarian Cancer in Young Women: Case Report and Review of the Literature.
    Anticancer Res. 2017;37:969-978.
    PubMed     Text format     Abstract available


    February 2017
  33. HA GS, Kim YW, Choi EH, Kim IY, et al
    Factors Associated with the Lack of Adjuvant Chemotherapy Following Curative Surgery for Stage II and III Colon Cancer: A Korean National Cohort Study.
    Anticancer Res. 2017;37:915-922.
    PubMed     Text format     Abstract available


  34. KANEKO M, Ishihara S, Murono K, Sasaki K, et al
    Carbohydrate Antigen 19-9 Predicts Synchronous Peritoneal Carcinomatosis in Patients with Colorectal Cancer.
    Anticancer Res. 2017;37:865-870.
    PubMed     Text format     Abstract available


  35. HAGLAND HR, Lea D, Watson MM, Soreide K, et al
    Correlation of Blood T-Cells to Intratumoural Density and Location of CD3+ and CD8+ T-Cells in Colorectal Cancer.
    Anticancer Res. 2017;37:675-683.
    PubMed     Text format     Abstract available


  36. IWATA N, Ishikawa T, Okazaki S, Mogushi K, et al
    Clinical Significance of Methylation and Reduced Expression of the Quaking Gene in Colorectal Cancer.
    Anticancer Res. 2017;37:489-498.
    PubMed     Text format     Abstract available


  37. CHUNG SS, Adekoya D, Enenmoh I, Clarke O, et al
    Salinomycin Abolished STAT3 and STAT1 Interactions and Reduced Telomerase Activity in Colorectal Cancer Cells.
    Anticancer Res. 2017;37:445-453.
    PubMed     Text format     Abstract available


  38. GALANOPOULOS M, Papanikolaou IS, Zografos E, Viazis N, et al
    Comparative Study of Mutations in Single Nucleotide Polymorphism Loci of KRAS and BRAF Genes in Patients Who Underwent Screening Colonoscopy, With and Without Premalignant Intestinal Polyps.
    Anticancer Res. 2017;37:651-657.
    PubMed     Text format     Abstract available


  39. LIBERALE G, Lecocq C, Garcia C, Muylle K, et al
    Accuracy of FDG-PET/CT in Colorectal Peritoneal Carcinomatosis: Potential Tool for Evaluation of Chemotherapeutic Response.
    Anticancer Res. 2017;37:929-934.
    PubMed     Text format     Abstract available


    January 2017

  40. Non-coding RNAs in Colorectal Cancer.
    Anticancer Res. 2017;37:369.
    PubMed     Text format    


  41. PASQUALETTI F, Montrone S, Vivaldi C, Zani M, et al
    Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer.
    Anticancer Res. 2017;37:315-319.
    PubMed     Text format     Abstract available


  42. FUJIYOSHI K, Yamamoto G, Takenoya T, Takahashi A, et al
    Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
    Anticancer Res. 2017;37:239-247.
    PubMed     Text format     Abstract available


  43. PARK M, Sundaramoorthy P, Sim JJ, Jeong KY, et al
    Synergistically Anti-metastatic Effect of 5-Flourouracil on Colorectal Cancer Cells via Calcium-mediated Focal Adhesion Kinase Proteolysis.
    Anticancer Res. 2017;37:103-114.
    PubMed     Text format     Abstract available


  44. IMAI T, Oue N, Sentani K, Sakamoto N, et al
    KIF11 Is Required for Spheroid Formation by Oesophageal and Colorectal Cancer Cells.
    Anticancer Res. 2017;37:47-55.
    PubMed     Text format     Abstract available


  45. SANTOS MD, Silva C, Rocha A, Nogueira C, et al
    Prognostic and Therapeutic Potential Implications of Genetic Variability in Prostaglandin E2 Pathway Genes in Rectal Cancer.
    Anticancer Res. 2017;37:281-291.
    PubMed     Text format     Abstract available


  46. ATTENBERGER UI, Ong MM, Rathmann N, Doyon F, et al
    mMRI at 3.0 T as an Evaluation Tool of Therapeutic Response to Neoadjuvant CRT in Patients with Advanced-stage Rectal Cancer.
    Anticancer Res. 2017;37:215-222.
    PubMed     Text format     Abstract available


  47. RUBIO CA
    Three Pathways of Colonic Carcinogenesis in Rats.
    Anticancer Res. 2017;37:15-20.
    PubMed     Text format     Abstract available


  48. MORIS D, Dimitroulis D, Vernadakis S, Papalampros A, et al
    Parenchymal-sparing Hepatectomy as the New Doctrine in the Treatment of Liver-metastatic Colorectal Disease: Beyond Oncological Outcomes.
    Anticancer Res. 2017;37:9-14.
    PubMed     Text format     Abstract available


    December 2016
  49. SUZUKI A, Kobayashi R, Fujii H, Iihara H, et al
    Control of Nausea and Vomiting in Patients with Colorectal Cancer Receiving Chemotherapy with Moderate Emetic Risk.
    Anticancer Res. 2016;36:6527-6533.
    PubMed     Text format     Abstract available


  50. NAGANO Y, Toiyama Y, Okugawa Y, Imaoka H, et al
    MicroRNA-7 Is Associated with Malignant Potential and Poor Prognosis in Human Colorectal Cancer.
    Anticancer Res. 2016;36:6521-6526.
    PubMed     Text format     Abstract available


  51. YEO MK, Lee YM, Seong IO, Choi SY, et al
    Up-regulation of Cytoplasmic CD24 Expression Is Associated with Malignant Transformation but Favorable Prognosis of Colorectal Adenocarcinoma.
    Anticancer Res. 2016;36:6593-6598.
    PubMed     Text format     Abstract available


  52. SHANY S, Sigal-Batikoff I, Lamprecht S
    Vitamin D and Myofibroblasts in Fibrosis and Cancer: At Cross-purposes with TGF-beta/SMAD Signaling.
    Anticancer Res. 2016;36:6225-6234.
    PubMed     Text format     Abstract available


    November 2016
  53. ICHIHARA H, Okumura M, Matsumoto Y
    Therapeutic Effects of Hybrid Liposomes Against Xenograft Mouse Model of Colorectal Cancer In Vivo Due to Long-term Accumulation.
    Anticancer Res. 2016;36:5875-5882.
    PubMed     Text format     Abstract available


  54. CHIEN CR, Chen WT, Wang HM, Ke TW, et al
    A Comparative Effectiveness Study of Two Oral Chemotherapy Drugs (UFT vs. Capecitabine) in Neoadjuvant Concurrent Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer.
    Anticancer Res. 2016;36:6155-6160.
    PubMed     Text format     Abstract available


    October 2016
  55. ALT M, Truant S, Renaud-Vantroys T, Sequier C, et al
    Bevacizumab Associated with Chemotherapy for Initially Non-resectable Liver Metastases from Colorectal Cancer: a Case-Control Study.
    Anticancer Res. 2016;36:5551-5555.
    PubMed     Text format     Abstract available


  56. SARLINOVA M, Halasa M, Mistuna D, Musak L, et al
    miR-21, miR-221 and miR-150 Are Deregulated in Peripheral Blood of Patients with Colorectal Cancer.
    Anticancer Res. 2016;36:5449-5454.
    PubMed     Text format     Abstract available


  57. YAMAOKA Y, Ikeda M, Ikenaga M, Murakami H, et al
    Anti-metastatic Effect of Short-term Postoperative Anticoagulation for Patients Undergoing Curative Resection of Colorectal Cancer.
    Anticancer Res. 2016;36:5425-5429.
    PubMed     Text format     Abstract available


  58. KODA K, Miyauchi H, Kosugi C, Kaiho T, et al
    Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
    Anticancer Res. 2016;36:5325-5331.
    PubMed     Text format     Abstract available


  59. ALFAYEZ M, Vishnubalaji R, Alajez NM
    Runt-related Transcription Factor 1 (RUNX1T1) Suppresses Colorectal Cancer Cells Through Regulation of Cell Proliferation and Chemotherapeutic Drug Resistance.
    Anticancer Res. 2016;36:5257-5263.
    PubMed     Text format     Abstract available


  60. ISEKI Y, Shibutani M, Maeda K, Nagahara H, et al
    Prognostic Significance of MicroRNA-21 Expression in Patients with Unresectable Metastatic Colon Cancer.
    Anticancer Res. 2016;36:5145-5151.
    PubMed     Text format     Abstract available


  61. SIDERIS M, Moorhead J, Diaz-Cano S, Bjarnason I, et al
    KRAS Mutant Status, p16 and beta-catenin Expression May Predict Local Recurrence in Patients Who Underwent Transanal Endoscopic Microsurgery (TEMS) for Stage I Rectal Cancer.
    Anticancer Res. 2016;36:5315-5324.
    PubMed     Text format     Abstract available


  62. ELZAGHEID A, Emaetig F, Elsaghayer W, Torjman F, et al
    Neurofibromin Expression is Associated with Aggressive Disease and Poor Outcome in Colorectal Carcinoma.
    Anticancer Res. 2016;36:5301-5306.
    PubMed     Text format     Abstract available


  63. BACZYNSKA D, Bombik I, Malicka-Blaszkiewicz M
    beta-Catenin Expression Regulates Cell Migration of Human Colonic Adenocarcinoma Cells Through Gelsolin.
    Anticancer Res. 2016;36:5249-5256.
    PubMed     Text format     Abstract available


  64. TAMPELLINI M, Benedetto S, Rubatto E, Baratelli C, et al
    Bioequivalence of Branded and Generic Oxaliplatin: From Preclinical Assessment to Clinical Incidence of Hypersensitivity Reactions.
    Anticancer Res. 2016;36:5163-5170.
    PubMed     Text format     Abstract available


  65. DE FELICE F, Musio D, Benevento I, Magnante A, et al
    Influence of Organ Invasion in Clinical Outcomes for Locally Advanced Rectal Cancer.
    Anticancer Res. 2016;36:5443-5447.
    PubMed     Text format     Abstract available


  66. BISCANIN A, Ljubicic N, Boban M, Balicevic D, et al
    CX43 Expression in Colonic Adenomas and Surrounding Mucosa Is a Marker of Malignant Potential.
    Anticancer Res. 2016;36:5437-5442.
    PubMed     Text format     Abstract available


  67. NONAKA T, Fukuda A, Maekawa K, Nagayoshi S, et al
    Clinical and Oncological Outcomes of Laparoscopic Versus Open Surgery for Advanced Rectal Cancer.
    Anticancer Res. 2016;36:5419-5424.
    PubMed     Text format     Abstract available


  68. RUBIO CA, Schmidt PT
    Gut-associated Lymphoid Tissue (GALT) Carcinoma or Dome Carcinoma?
    Anticancer Res. 2016;36:5385-5387.
    PubMed     Text format     Abstract available


    September 2016
  69. KISS I, Mlcochova J, Bortlicek Z, Poprach A, et al
    Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients.
    Anticancer Res. 2016;36:4955-9.
    PubMed     Text format     Abstract available


  70. LIBERALE G, Vankerckhove S, Galdon MG, Larsimont D, et al
    Sentinel Lymph Node Detection by Blue Dye Versus Indocyanine Green Fluorescence Imaging in Colon Cancer.
    Anticancer Res. 2016;36:4853-8.
    PubMed     Text format     Abstract available


  71. PIKOULIS E, Margonis GA, Andreatos N, Sasaki K, et al
    Prognostic Role of BRAF Mutations in Colorectal Cancer Liver Metastases.
    Anticancer Res. 2016;36:4805-11.
    PubMed     Text format     Abstract available


  72. NAKANISHI M, Kuriu Y, Murayama Y, Arita T, et al
    Usefulness of Reduced Port Surgery for Left Colon Cancer.
    Anticancer Res. 2016;36:4749-52.
    PubMed     Text format     Abstract available


  73. KAWAGUCHI D, Hiroshima Y, Matsuo K, Endo I, et al
    Hepatic Resection After Prehepatectomy Chemotherapy for Metastatic Colorectal Cancer: A Propensity-Matched Analysis.
    Anticancer Res. 2016;36:4725-30.
    PubMed     Text format     Abstract available


  74. RACHAR V, Czejka M, Kitzmueller M, Buchner P, et al
    Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients.
    Anticancer Res. 2016;36:4715-23.
    PubMed     Text format     Abstract available


  75. STANKEVICIUS V, Vasauskas G, Noreikiene R, Kuodyte K, et al
    Extracellular Matrix-dependent Pathways in Colorectal Cancer Cell Lines Reveal Potential Targets for Anticancer Therapies.
    Anticancer Res. 2016;36:4559-67.
    PubMed     Text format     Abstract available


  76. TANAKA R, Tomosugi M, Sakai T, Sowa Y, et al
    MEK Inhibitor Suppresses Expression of the miR-17-92 Cluster with G1-Phase Arrest in HT-29 Human Colon Cancer Cells and MIA PaCa-2 Pancreatic Cancer Cells.
    Anticancer Res. 2016;36:4537-43.
    PubMed     Text format     Abstract available


  77. LING E, Ringel A, Sigal-Batikoff I, Abu-Freha N, et al
    Human Colorectal Cancer Stage-dependent Global DNA Hypomethylation of Cancer-associated Fibroblasts.
    Anticancer Res. 2016;36:4503-7.
    PubMed     Text format     Abstract available


  78. YUN CW, Yun S, Lee JH, Han YS, et al
    Silencing Prion Protein in HT29 Human Colorectal Cancer Cells Enhances Anticancer Response to Fucoidan.
    Anticancer Res. 2016;36:4449-58.
    PubMed     Text format     Abstract available


  79. HOLUBEC L, Polivka J Jr, Safanda M, Karas M, et al
    The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment.
    Anticancer Res. 2016;36:4421-6.
    PubMed     Text format     Abstract available


  80. DA SILVA FC, Wernhoff P, Dominguez-Barrera C, Dominguez-Valentin M, et al
    Update on Hereditary Colorectal Cancer.
    Anticancer Res. 2016;36:4399-405.
    PubMed     Text format     Abstract available


  81. SHIN YR, Kim KA, Im S, Hwang SS, et al
    Prediction of KRAS Mutation in Rectal Cancer Using MRI.
    Anticancer Res. 2016;36:4799-804.
    PubMed     Text format     Abstract available


  82. KAWAGUCHI D, Hiroshima Y, Matsuo K, Endo I, et al
    Parenchymal Congestion Is Important for Rapid Regeneration of the Future Liver Remnant Following the ALPPS Procedure.
    Anticancer Res. 2016;36:4731-8.
    PubMed     Text format     Abstract available


  83. ATANASOVA S, Nikolova B, Murayama S, Stoyanova E, et al
    Electroinduced Delivery of Hydrogel Nanoparticles in Colon 26 Cells, Visualized by Confocal Fluorescence System.
    Anticancer Res. 2016;36:4601-6.
    PubMed     Text format     Abstract available


  84. KAPPIL M, Terry MB, Delgado-Cruzata L, Liao Y, et al
    Mismatch Repair Polymorphisms as Markers of Breast Cancer Prevalence in the Breast Cancer Family Registry.
    Anticancer Res. 2016;36:4437-41.
    PubMed     Text format     Abstract available


    August 2016
  85. SUEDA T, Sakai D, Kudo T, Sugiura T, et al
    Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
    Anticancer Res. 2016;36:4299-306.
    PubMed     Text format     Abstract available


  86. MONTAGNANI F, DI Leonardo G, Pino MS, Martella F, et al
    Progression-free Survival as a Surrogate End-point in Advanced Colorectal Cancer Treated with Antiangiogenic Therapies.
    Anticancer Res. 2016;36:4259-65.
    PubMed     Text format     Abstract available


  87. PLOQUIN A, Zerimech F, Escande F, Adenis A, et al
    Lack of Relationship Between Clinical Features and KRAS Mutations in Patients with Metastatic Colorectal Cancer.
    Anticancer Res. 2016;36:4233-6.
    PubMed     Text format     Abstract available


  88. KUNIZAKI M, Sawai T, Takeshita H, Tominaga T, et al
    Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Colorectal Cancer.
    Anticancer Res. 2016;36:4171-5.
    PubMed     Text format     Abstract available


  89. BABA H, Ishikawa T, Mogushi K, Ishiguro M, et al
    Identification of SATB1 as a Specific Biomarker for Lymph Node Metastasis in Colorectal Cancer.
    Anticancer Res. 2016;36:4069-76.
    PubMed     Text format     Abstract available


  90. DJAAFAR S, Dunand-Sautier I, Gonelle-Gispert C, Lacotte S, et al
    Enoxaparin Attenuates Mouse Colon Cancer Liver Metastases by Inhibiting Heparanase and Interferon-gamma-inducible Chemokines.
    Anticancer Res. 2016;36:4019-32.
    PubMed     Text format     Abstract available


  91. ILHAN N, Gungor H, Gul HF, Eroksuz H, et al
    Expression of Endoglin and Vascular Endothelial Growth Factor as Prognostic Markers in Experimental Colorectal Cancer.
    Anticancer Res. 2016;36:3953-9.
    PubMed     Text format     Abstract available


  92. KUMASHIRO R, Konishi K, Chiba T, Akahoshi T, et al
    Integrated Endoscopic System Based on Optical Imaging and Hyperspectral Data Analysis for Colorectal Cancer Detection.
    Anticancer Res. 2016;36:3925-32.
    PubMed     Text format     Abstract available


  93. MEEKS MW, Grace S, Chen Y, Petterchak J, et al
    Synchronous Quadruple Primary Neoplasms: Colon Adenocarcinoma, Collision Tumor of Neuroendocrine Tumor and Schwann Cell Hamartoma and Sessile Serrated Adenoma of the Appendix.
    Anticancer Res. 2016;36:4307-11.
    PubMed     Text format     Abstract available


  94. ETO K, Kosuge M, Ohkuma M, Haruki K, et al
    Comparison of Transumbilical and Conventional Defunctioning Ileostomy in Laparoscopic Anterior Resections for Rectal Cancer.
    Anticancer Res. 2016;36:4139-44.
    PubMed     Text format     Abstract available


  95. PICARDI V, Deodato F, Guido A, Giaccherini L, et al
    Concurrent Chemoradiation with Concomitant Boost in Locally Advanced Rectal Cancer: A Phase II Study.
    Anticancer Res. 2016;36:4081-7.
    PubMed     Text format     Abstract available


    July 2016
  96. SHIRAIWA S, Kinugasa T, Kawahara A, Mizobe T, et al
    Nuclear Y-Box-binding Protein-1 Expression Predicts Poor Clinical Outcome in Stage III Colorectal Cancer.
    Anticancer Res. 2016;36:3781-8.
    PubMed     Text format     Abstract available


  97. YOSHIDA Y, Naito M, Yamada T, Aisu N, et al
    Adoptive Chemoimmunotherapy Using Activated alphabeta T Cells for Stage IV Colorectal Cancer.
    Anticancer Res. 2016;36:3741-6.
    PubMed     Text format     Abstract available


  98. MUKOHYAMA J, Shimono Y, Yamashita K, Sumi Y, et al
    Effect of Xenotransplantation Site on MicroRNA Expression of Human Colon Cancer Stem Cells.
    Anticancer Res. 2016;36:3679-86.
    PubMed     Text format     Abstract available


  99. YAMAGUCHI T, Iwasa S, Nagashima K, Ikezawa N, et al
    Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer.
    Anticancer Res. 2016;36:3531-6.
    PubMed     Text format     Abstract available


  100. MATSUI T, Nagata N, Hirata K, Okazaki S, et al
    Bi-weekly Capecitabine-Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer -The PHOENiX Trial.
    Anticancer Res. 2016;36:3437-43.
    PubMed     Text format     Abstract available


  101. CHUNG YH, Kim D
    Enhanced TLR4 Expression on Colon Cancer Cells After Chemotherapy Promotes Cell Survival and Epithelial-Mesenchymal Transition Through Phosphorylation of GSK3beta.
    Anticancer Res. 2016;36:3383-94.
    PubMed     Text format     Abstract available


  102. KANG BW, Jeon HS, Chae YS, Lee SJ, et al
    Impact of Genetic Variation in MicroRNA-binding Site on Susceptibility to Colorectal Cancer.
    Anticancer Res. 2016;36:3353-61.
    PubMed     Text format     Abstract available


  103. YAMASAKI K, Matsui T, Hisabe T, Yano Y, et al
    Retrospective Analysis of Growth Speed of 54 Lesions of Colitis-associated Colorectal Neoplasia.
    Anticancer Res. 2016;36:3731-40.
    PubMed     Text format     Abstract available


  104. SAKAUE M, Maeda K, Ohno S, Ito T, et al
    Screening for Identification of Personalized Food to Promote Adiponectin Secretion in Patients with Cancer.
    Anticancer Res. 2016;36:3673-7.
    PubMed     Text format     Abstract available


  105. ALIBERTI C, Carandina R, Sarti D, Mulazzani L, et al
    Hepatic Arterial Infusion of Polyethylene Glycol Drug-eluting Beads for Primary and Metastatic Liver Cancer Therapy.
    Anticancer Res. 2016;36:3515-21.
    PubMed     Text format     Abstract available


  106. AKINWANDE O, Scoggins C, Martin RC
    Early Experience with 70-150 mum Irinotecan Drug-eluting Beads (M1-DEBIRI) for the Treatment of Unresectable Hepatic Colorectal Metastases.
    Anticancer Res. 2016;36:3413-8.
    PubMed     Text format     Abstract available


    June 2016

  107. Laparoscopic Surgery for Colorectal Cancer.
    Anticancer Res. 2016;36:3225.
    PubMed     Text format    


  108. BRADATSCH A, Kornprat P, Bacher H, Cerwenka H, et al
    The Value of Lymph Node Dissection in the Surgery of Colorectal Cancer Liver Metastases.
    Anticancer Res. 2016;36:2993-7.
    PubMed     Text format     Abstract available


  109. HENKENBERENS C, Toklu H, Tamme C, Bruns F, et al
    Clinical Value of Squamous Cell Carcinoma Antigen (SCCAg) in Anal Cancer - A Single-Center Retrospective Analysis.
    Anticancer Res. 2016;36:3173-7.
    PubMed     Text format     Abstract available


  110. MIYAMOTO J, Michaud AL, Harandi NK, Kim EJ, et al
    The Role of Image-guided Radiotherapy in the Treatment of Anorectal Cancer Using Prone Belly-board Positioning.
    Anticancer Res. 2016;36:3013-7.
    PubMed     Text format     Abstract available


  111. SODRING M, Gunnes G, Paulsen JE
    Detection and Characterization of Flat Aberrant Crypt Foci (Flat ACF) in the Novel A/J Min/+ Mouse.
    Anticancer Res. 2016;36:2745-50.
    PubMed     Text format     Abstract available


  112. NASIR A, Reising LO, Nedderman DM, Fulford AD, et al
    Heterogeneity of Vascular Endothelial Growth Factor Receptors 1, 2, 3 in Primary Human Colorectal Carcinoma.
    Anticancer Res. 2016;36:2683-96.
    PubMed     Text format     Abstract available


  113. HAO X, Xiao H, Ju J, Hewitt SM, et al
    Decreased Expression of Retinoid X Receptors During Human and Azoxymethane-induced Colorectal Carcinogenesis in the Rat.
    Anticancer Res. 2016;36:2659-64.
    PubMed     Text format     Abstract available


    May 2016
  114. SADAHIRO S, Suzuki T, Tanaka A, Okada K, et al
    Increase in Gene Expression of TYMP, DPYD and HIF1A Are Associated with Response to Preoperative Chemoradiotherapy Including S-1 or UFT for Rectal Cancer.
    Anticancer Res. 2016;36:2433-40.
    PubMed     Text format     Abstract available


  115. WISNIEWSKI J, Wesolowska O, Sroda-Pomianek K, Paprocka M, et al
    Euphorbia Species-derived Diterpenes and Coumarins as Multidrug Resistance Modulators in Human Colon Carcinoma Cells.
    Anticancer Res. 2016;36:2259-64.
    PubMed     Text format     Abstract available


  116. RADIC J, Kruslin B, Samija M, Ulamec M, et al
    Connexin 43 Expression in Primary Colorectal Carcinomas in Patients with Stage III and IV Disease.
    Anticancer Res. 2016;36:2189-96.
    PubMed     Text format     Abstract available


  117. YAMAUCHI K, Kokuryo T, Yokoyama Y, Uehara K, et al
    Prediction of Early Recurrence After Curative Resection of Colorectal Liver Metastasis and Subsequent S-1 Chemotherapy.
    Anticancer Res. 2016;36:2175-9.
    PubMed     Text format     Abstract available


  118. TRESKA V
    Methods to Increase Future Liver Remnant Volume in Patients with Primarily Unresectable Colorectal Liver Metastases: Current State and Future Perspectives.
    Anticancer Res. 2016;36:2065-71.
    PubMed     Text format     Abstract available


    April 2016
  119. ABRAMS MJ, Koffer PP, Leonard KL
    The Emerging Non-operative Management of Non-metastatic Rectal Cancer: A Population Analysis.
    Anticancer Res. 2016;36:1699-702.
    PubMed     Text format     Abstract available


  120. KORBER MI, Staribacher A, Ratzenbock I, Steger G, et al
    NFkappaB-Associated Pathways in Progression of Chemoresistance to 5-Fluorouracil in an In Vitro Model of Colonic Carcinoma.
    Anticancer Res. 2016;36:1631-9.
    PubMed     Text format     Abstract available


  121. FRANCO P, Arcadipane F, Ragona R, Mistrangelo M, et al
    Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
    Anticancer Res. 2016;36:2027-32.
    PubMed     Text format     Abstract available


  122. SUMRIEN H, Dadnam C, Hewitt J, McCarthy K, et al
    Feasibility of Transanal Minimally Invasive Surgery (TAMIS) for Rectal Tumours and Its Impact on Quality of Life - The Bristol Series.
    Anticancer Res. 2016;36:2005-9.
    PubMed     Text format     Abstract available


  123. TANAKAYA K, Yamaguchi T, Ishikawa H, Hinoi T, et al
    Causes of Cancer Death Among First-Degree Relatives in Japanese Families with Lynch Syndrome.
    Anticancer Res. 2016;36:1985-9.
    PubMed     Text format     Abstract available


  124. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.
    Anticancer Res. 2016;36:1973-8.
    PubMed     Text format     Abstract available


  125. FRANCO P, Arcadipane F, Ragona R, Mistrangelo M, et al
    Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
    Anticancer Res. 2016;36:1943-8.
    PubMed     Text format     Abstract available


  126. NAKANISHI M, Kuriu Y, Murayama Y, Arita T, et al
    A Study on the Tolerability of Capecitabine plus Oxaliplatin as Adjuvant Chemotherapy.
    Anticancer Res. 2016;36:1851-4.
    PubMed     Text format     Abstract available


  127. ROMANO M, DE Francesco F, Zarantonello L, Ruffolo C, et al
    From Inflammation to Cancer in Inflammatory Bowel Disease: Molecular Perspectives.
    Anticancer Res. 2016;36:1447-60.
    PubMed     Text format     Abstract available


    March 2016
  128. WU BO, Jiang WG, Zhou D, Cui YX, et al
    Knockdown of EPHA1 by CRISPR/CAS9 Promotes Adhesion and Motility of HRT18 Colorectal Carcinoma Cells.
    Anticancer Res. 2016;36:1211-9.
    PubMed     Text format     Abstract available


  129. HUANG Y, Alzahrani NA, Chua TC, Huo YR, et al
    Clinical Outcomes of Patients with Extensive Peritoneal Carcinomatosis Following Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy.
    Anticancer Res. 2016;36:1033-40.
    PubMed     Text format     Abstract available


  130. ISHIKAWA T, Uetake H, Murotani K, Kobunai T, et al
    Genome-wide DNA Copy-number Analysis in ACTS-CC Trial of Adjuvant Chemotherapy for Stage III Colonic Cancer.
    Anticancer Res. 2016;36:853-60.
    PubMed     Text format     Abstract available


  131. HADAC JN, Miller DD, Grimes IC, Clipson L, et al
    Heterochromatin Protein 1 Binding Protein 3 Expression as a Candidate Marker of Intrinsic 5-Fluorouracil Resistance.
    Anticancer Res. 2016;36:845-52.
    PubMed     Text format     Abstract available


    February 2016
  132. KUCERA R, Topolcan O, Fiala O, Kinkorova J, et al
    The Role of TPS and TPA in the Diagnostics of Distant Metastases.
    Anticancer Res. 2016;36:773-7.
    PubMed     Text format     Abstract available


  133. JUNGINGER T, Goenner U, Hitzler M, Trinh TT, et al
    Influence of Local Recurrence and Distant Metastasis on Prognosis After Local Excision of Rectal Carcinoma.
    Anticancer Res. 2016;36:763-8.
    PubMed     Text format     Abstract available


  134. UEKI T, Manabe T, Inoue S, Ienaga J, et al
    A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer.
    Anticancer Res. 2016;36:741-7.
    PubMed     Text format     Abstract available


    January 2016
  135. KAWAHARA H, Misawa T, Watanabe K, Hojo S, et al
    Feasibility of Single-incision Laparoscopic Surgery plus One Assist Port for Anterior Resection.
    Anticancer Res. 2016;36:467-9.
    PubMed     Text format     Abstract available


  136. ZEZULOVA M, Bartouskova M, Hlidkova E, Juranova J, et al
    Prognostic Significance of Serum and Urinary Neopterin Concentrations in Patients with Rectal Carcinoma Treated with Chemoradiation.
    Anticancer Res. 2016;36:287-92.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: